What is Propanc Biopharma, Inc. Common Stock?
, a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.04M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.